Position in URGN
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$30,637,003
-$74,135,833 QoQ
Shares Held
1,703,949
-61.9% QoQ
Ownership
3.50%
of shares outstanding
% of Portfolio
0.63%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2025
3 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in URGN Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Paradigm Biocapital Advisors LP holds $4,894,261,596 across 35 Biotechnology names. URGN ranks #29 (0.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ACLX |
Arcellx, Inc.
|
5,774,016 | $662,972,517 | |
| 2 | RVMD |
Revolution Medicines, Inc.
|
6,655,703 | $647,267,116 | |
| 3 | NUVL |
Nuvalent, Inc.
|
5,324,433 | $545,488,160 | |
| 4 | PCVX |
Vaxcyte, Inc.
|
4,793,020 | $278,522,392 | |
| 5 | EWTX |
Edgewise Therapeutics, Inc.
|
7,365,038 | $231,998,697 | |
| 6 | GMAB |
Genmab A/S
|
7,967,836 | $213,777,039 | |
| 7 | INSM |
INSMED Inc
|
1,254,488 | $205,133,877 | |
| 8 | TARS |
Tarsus Pharmaceuticals, Inc.
|
2,562,154 | $179,735,103 |
All Filings in URGN
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $30,637,003 | 1,703,949 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $104,772,836 | 4,473,648 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $84,110,875 | 4,216,084 | Shares | Sole | 2025-11-14 | |
| 2025-08-05 | $48,320,407 | 2,332,066 | Shares | Sole | 2025-08-12 | |
| No filing history on record for this holder in this stock. | ||||||